IONIS PHARMACEUTICALS INC IONS
ASignal's systematic analysis rates IONS as Bearish.
Reflects the latest available analysis · analyzed Nov 15, 2026
The case on IONS
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (54.9% YoY)
- High cash position ($1.94B)
- Current ratio of 5.42x indicates strong liquidity
- RSI at 17.86 suggests deep oversold condition
- Negative operating cash flow (-$544.41M)
- High debt-to-equity ratio (5.52x)
- Negative profit and operating margins
- Negative EV/EBITDA (-9.25x) and forward P/E (-17.24x)
- MACD below signal line with expanding negative histogram
- Price trading well below SMA20 and SMA50
See the full verdict on IONS
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes IONS
Most investors never get a second opinion, let alone several. ASignal runs IONS past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.